Advertisement
OPK vs XAIR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OPK is a Hold and XAIR is a Buy.
OPK's RSI Indicator climbs out of oversold territory
The RSI Indicator for OPK moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 24 of the 29 cases the stock moved higher. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on OPK as a result. In 71 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for OPK just turned positive on October 19, 2026. Looking at past instances where OPK's MACD turned positive, the stock continued to rise in 33 of 40 cases over the following month. The odds of a continued upward trend are 82%.
OPK moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for OPK crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +3.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where OPK advanced for three days, in 159 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
OPK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 90 of 141 cases where OPK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OPK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.084) is normal, around the industry mean (65.876). P/E Ratio (-24.571) is within average values for comparable stocks, (3.542). Projected Growth (PEG Ratio) (0.270) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.134) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. OPK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OPK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Momentum Indicator for XAIR turns positive, indicating new upward trend
XAIR saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 101 similar instances where the indicator turned positive. In 84 of the 101 cases, the stock moved higher in the following days. The odds of a move higher are at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where XAIR's RSI Oscillator exited the oversold zone, 34 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
Following a +7.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where XAIR advanced for three days, in 177 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
XAIR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 45 cases where XAIR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XAIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for XAIR entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.144) is normal, around the industry mean (4.170). P/E Ratio (-0.038) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.213) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. XAIR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XAIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
OPK | XAIR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 41 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 31 Undervalued | 41 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 100 | |
PRICE GROWTH RATING 1..100 | 39 | 91 | |
P/E GROWTH RATING 1..100 | 85 | 8 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
OPK's Valuation (31) in the Biotechnology industry is in the same range as XAIR (41) in the null industry. This means that OPK’s stock grew similarly to XAIR’s over the last 12 months.
OPK's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as XAIR (100) in the null industry. This means that OPK’s stock grew similarly to XAIR’s over the last 12 months.
OPK's SMR Rating (92) in the Biotechnology industry is in the same range as XAIR (100) in the null industry. This means that OPK’s stock grew similarly to XAIR’s over the last 12 months.
OPK's Price Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for XAIR (91) in the null industry. This means that OPK’s stock grew somewhat faster than XAIR’s over the last 12 months.
XAIR's P/E Growth Rating (8) in the null industry is significantly better than the same rating for OPK (85) in the Biotechnology industry. This means that XAIR’s stock grew significantly faster than OPK’s over the last 12 months.
| OPK | XAIR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 83% | 2 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 79% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 76% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 82% | N/A |
| TrendWeek ODDS (%) | 2 days ago 76% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 75% | 2 days ago 90% |
| Advances ODDS (%) | 6 days ago 74% | 6 days ago 77% |
| Declines ODDS (%) | 27 days ago 80% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 64% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
OPK’s FA Score shows that 1 FA rating(s) are green while XAIR’s FA Score has 1 green FA rating(s).
- OPK’s FA Score: 1 green, 4 red.
- XAIR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
OPK’s TA Score shows that 8 TA indicator(s) are bullish while XAIR’s TA Score has 4 bullish TA indicator(s).
- OPK’s TA Score: 8 bullish, 2 bearish.
- XAIR’s TA Score: 4 bullish, 3 bearish.
Price Growth
OPK (@Medical Specialties) experienced а +5.52% price change this week, while XAIR (@Medical/Nursing Services) price change was +3.27% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -2.34%. For the same industry, the average monthly price growth was -5.26%, and the average quarterly price growth was +42.07%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +0.01%. For the same industry, the average monthly price growth was -6.09%, and the average quarterly price growth was -8.21%.
Reported Earning Dates
OPK is expected to report earnings on Nov 04, 2026.
XAIR is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Medical Specialties (-2.34% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (+0.01% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
OPK and
Correlation & Price change
A.I.dvisor indicates that over the last year, OPK has been loosely correlated with ICUI. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if OPK jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To OPK | 1D Price Change % | ||
|---|---|---|---|---|
| OPK | 100% | N/A | ||
| ICUI - OPK | 41% Loosely correlated | -0.34% | ||
| CLPT - OPK | 39% Loosely correlated | -2.41% | ||
| CRL - OPK | 36% Loosely correlated | +3.94% | ||
| IQV - OPK | 36% Loosely correlated | +1.61% | ||
| UTMD - OPK | 36% Loosely correlated | -0.75% | ||
More | ||||
XAIR and
Correlation & Price change
A.I.dvisor indicates that over the last year, XAIR has been loosely correlated with OPK. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if XAIR jumps, then OPK could also see price increases.
| Ticker / NAME | Correlation To XAIR | 1D Price Change % | ||
|---|---|---|---|---|
| XAIR | 100% | +4.98% | ||
| OPK - XAIR | 35% Loosely correlated | N/A | ||
| KIDS - XAIR | 32% Poorly correlated | +3.22% | ||
| CERS - XAIR | 31% Poorly correlated | -0.85% | ||
| IDXX - XAIR | 31% Poorly correlated | +0.06% | ||
| RVTY - XAIR | 31% Poorly correlated | +7.84% | ||
More | ||||